Pfizer (NYSE:PFE) on Tuesday announced that a Phase 3 trial designed to test its FDA-approved antitumor agent Tukysa as a ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...

Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...

This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

Pfizer's Tukysa could become the first update to the maintenance regimen for HER2-positive breast cancer in over a decade if ...

Can Pfizer’s GDF15-blocking, appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help ...

Pfizer has agreed to acquire Metsera, a company specializing in weight-loss medications, for $47.50 per share in cash, along ...

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...

() -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...